Link between cervical cancer screening guidelines and preterm delivery among young females

Written By : Isra Zaman

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-07-25 03:30 GMT | Update On 2023-07-25 09:27 GMT

Findings of a recent cross-sectional study published in JAMA Health Forum suggest that additional recommended cervical cancer screenings before birth were associated with an increased risk of Preterm Delivery. These results can be used in future simulation models integrating oncological trade-offs to help ascertain optimal screening strategies.

The research by Rebecca A. Bromley-Dulfano et al, aimed to ascertain the population-level association between the number of guideline-recommended cervical cancer screenings and downstream Preterm Delivery risk among females aged 18 to 24 years.

National Vital Statistics System data from females aged 18 to 24 years who had a singleton, nulliparous birth in the US between 1996 and 2018 were used. Regression models were adjusted for maternal educational level, race and ethnicity, comorbidities, marital status, and prenatal care visits. Data were analyzed between June 2020 and March 2023.

The mean number of guideline-recommended screenings by time of childbirth was 2.4. Overall, Preterm Delivery and very preterm delivery occurred in 10.1% and 2.9% of births, respectively. One additional recommended screening was associated with a 0.073 percentage-point increase in Preterm Delivery risk but no statistically significant change in very preterm delivery risk. Females with hypertension or diabetes had a higher increase in Preterm Delivery risk than those without these comorbidities.

Reference:Bromley-Dulfano RA, Rossin-Slater M, Bundorf MK. Association Between Cervical Cancer Screening Guidelines and Preterm Delivery Among Females Aged 18 to 24 Years. JAMA Health Forum. 2023;4(7):e231974. doi:10.1001/jamahealthforum.2023.1974

Full View

Article Source : JAMA Helath Forum

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Isra Zaman

Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Link between cervical cancer screening guidelines and preterm delivery among young females

Similar News

Alkem Launches 'PRAYAS': A Bold Step Toward Accessible Cancer Care

Study Links Hormone Therapy to Breast Cancer Risk in Women Under 55

Blood Test Could Replace Bone Marrow Biopsy for Leukemia Detection: Study Finds

New Cancer Test May Identify Who Won't Respond to Chemotherapy: Study Suggests

Survey Reveals Only 13 Percent Know Testicular Cancer Hits Men Under 40

Smarter, Cheaper, Faster AI Tool for Cancer Monitoring: Study Finds

How Early Can Cancer Be Detected Before Symptoms Appear? Study Sheds Light

New Nanoparticles Therapy for Patients with Lung Cancer, Cystic Fibrosis: Study Finds